Copyright © 2019 by  S M Discovery Group. All rights reserved.

ADVISORY BOARD

Professor Moein Moghimi
Co - Founder

Dr.  Moein Moghimi, PhD. is a renowned expert in pharmaceutical nanoscience, nanomedicine and nanosafety and has published extensively in these areas. Since August 2017, Dr. Moghimi is a Professor of Pharmaceutics (School of Pharmacy) and Research Professor (Institute of Cellular Medicine) at Newcastle University (UK). Prior to this he was Professor and Chair in Pharmaceutics at the School of Medicine, Pharmacy and Health, Durham University (UK).

 

Dr. Moghimi was also formerly a Full Affiliate Member/Professor at the Department of Translational Imaging, Houston Methodist Research Institute, Houston Methodist Hospital Systems (Houston, Texas, USA) and is currently an Adjoint Professor at the Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Denver Medical Center (USA). In 2015, Moein was a Visiting Professor at Università Degli Studi Di Padova, Italy. Between 2008 and March 2016, he was based at the University of Copenhagen (Denmark) serving as Professor of Nanomedicine at the Department of Pharmacy, Professor of Pharmaceutical Nanotechology at the NanoScience Centre, and the Founder and Director of the multi-million Euro Centre for Pharmaceutical Nanotechnology and Nanotoxiocology (the first interdisciplinary nanomedicine research centre in Denmark). Between 2008 and 2010, he further served as the Honorary Professor of Nanomedicine at the Multidisciplinary Research Center, Shantou University (China). His earlier appointments included a Senior Lectureship position in Biopharmacy and Molecular Pharmaceutics at the School of Pharmacy, University of Brighton and The University Research Fellow in Advanced Drug Delivery Systems at the Department of Pharmaceutical Sciences, University of Nottingham.

 

Over the past two decades, Professor Moghimi has been practicing in the capacity of advisor/consultant to over 50 pharmaceutical, biotechnology, health and food industries as well as investment banks, management consultancy firms and other entrepreneurial enterprises worldwide. He is a regular invited assessor and expert evaluator in nanomedicine/nanosafety programmes for governmental bodies, research councils and private organizations (over 50 establishments in 25 countries).

Professor Moghimi’s research activities are focused on pharmaceutical nanoscience, nanomedicine and nanosafety. More specifically, Professor Moghimi has made a major contribution to design and surface engineering of nanoparticles and functional nanosystems for parenteral site-specific targeting/drug delivery and imaging modalities (splenotropic entities, lymphotropic agents, ‘phagocyte-resistant’ nanoparticles, cerebral endothelial cell specific nanoplatforms and anti-cancer nanomedicine) as well as mechanistic understanding of nanomaterial/polymer-mediated infusion reactions and cell death processes. Professor Moghimi’s interdisciplinary research has been recognized by many international awards and to date he has been able to secure over €10 million in competitive research funds as principal investigator. Furthermore, he has partnered large-scale competitive European Commission FP-7 programmes in translational nanomedicine/drug delivery, addressing Alzheimer’s disease (The NAD Project) and atherosclerosis (CosmoPHOS NANO). In 2014 the NAD project was published as success story by Horizon 2020, endorsed by the EU President and received the prestigious Best Project Award in the category of completed projects under the European Union Framework programme in the field of industrial technologies. As of 2016, Professor Moghimi has edited multiple journal issues and is an author on >200 peer-reviewed journal articles and >10 patent/disclosure applications. He has given >300 invited seminars and keynotes in more than 30 countries.

 

Following completion of secondary education at d’Overbroeck’s College Oxford (UK), Moein studied biochemistry at the University of Manchester (UK) and in 1989 earned his PhD in biochemistry from Charing Cross and Westminster Medical School (Imperial College). He then completed a four-year SERC-funded post-doctoral training programme in Advanced Drug Delivery Research at the School of Pharmaceutical Sciences (University of Nottingham, UK).

Professor Dennis Choi
 

Dr. Dennis W. Choi is Professor and Chair of the Department of Neurology and Director of Stony Brook University’s Neurosciences Institute.  Dr. Choi is a co-discoverer of the physiological mechanism of action of benzodiazepine drugs, and a pioneer in dissecting processes responsible for pathological neurodegeneration and devising neuroprotective countermeasures. His laboratory identified a key role for NMDA receptor activation and calcium overload in excitotoxicity, and zinc in ischemic brain injury. Later work examined how apoptosis, potassium efflux, and several cell signaling pathways contribute to neuronal death. During the 1990s "Decade of the Brain" his lab was ranked by Science Watch #19 worldwide for highly cited neuroscience publications, and recognized by several awards, including the Wakeman Award, the Conte Award, the Ho-Am Prize, and the Reeve Medal.

More recently he has led neuroscience programs in the pharmaceutical industry, and in a private foundation, including those aimed at biomarker development and the early clinical testing of novel candidate therapies for nervous system diseases. He is a founding co-editor of the journal "Neurobiology of Disease", member of the IOM, a fellow of the AAAS, a past President of the Society for Neuroscience, and a past Vice President of the American Neurological Association. He has served on advisory committees to multiple public and private organizations, including HHS, FDA, NIH, and the IOM, and currently serves as Director of the Brain Science Institute at the Korea Institute of Science and Technology.

Dennis W. Choi, M.D., Ph.D., was on the faculty of Stanford University in the 1980s, and served as the Jones Professor and Head of Neurology at Washington University in St. Louis during the 1990s, leaving in January 2001 to work in industry (Merck). While a faculty member at Washington University, Choi was a key contributor to research on glutamate-mediated toxicity ("excitotoxicity") as a mechanism of neural injury in stroke and traumatic brain injury.

Choi attended Harvard College, from which he graduated in 1974, and went on to Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology to receive an MD and a PhD in Pharmacology in 1978. As a graduate student he demonstrated that benzodiazepines augment GABA-A receptor function, which represents a seminal discovery in neuroscience. Choi also completed his residency and fellowship in Neurology at Harvard.

Professor Emeritus Marc  Dichter

Marc Dichter, M.D., Ph.D. is Professor of Neurology and Pharmacology at the University of Pennsylvania.  He is the former Director of the David Mahoney Institute of Neurosciences and had served for twenty years as Director of the Penn Epilepsy Center. 

Dr. Dichter received his undergraduate education at Queens College of the City University of New York, and obtained an MD and PhD from New York University School of Medicine.  He trained in Medicine and Neurology at the Harvard-Longwood program.  He spent two years doing research at the NIH, after which he joined the faculty of Harvard Medical School.  After fourteen years at Harvard, he joined the faculty of the University of Pennsylvania School of Medicine in 1986. 

 

Dr. Dichter is active as a clinician, clinical researcher, basic researcher, educator and academic administrator.  His research has focused on both basic neuroscience and clinical investigations.  He has contributed significantly to the understanding of basic mechanisms underlying epilepsy, mechanisms of action of antiepileptic drugs, and the process of epileptogenesis.  Dr. Dichter’s research also involves translational and clinical studies in new approaches to treating intractable epilepsy, methods for preventing epilepsy, and neuroprotection.  He has been involved in the evaluation of many of the new antiepileptic drugs developed in the last three decades and co-directs a semi-annual conference in antiepileptic drug development that has been ongoing for more than 20 years.  He was most recently the PI of a DOD/USArmy sponsored pilot clinical trial using Topiramate to prevent epilepsy after traumatic brain injury and has been working with the VA system to enhance the treatment of war injured veterans, especially with regard to the problem of post-traumatic epilepsy. Dr. Dichter serves as the Chair of the National Advisory Committee overseeing the new VA Epilepsy Centers of Excellence.  Dr. Dichter has also worked in neurovirology, neuroimmunology, Alzheimer’s disease, amyotrophic lateral sclerosis, and other neurological areas over the past four decades.  He also currently teaches a course on understanding brain diseases (both neurological and psychiatric) to undergraduate students at Penn which is largely based on a course he pioneered for graduate students in multiple neuroscience-related fields at Penn.

 

Dr. Dichter has published more than 110 research papers and 62 chapters and reviews, and has edited four books.  Dr. Dichter has been continuously funded by the NIH for more than four decades and is currently the PI of a training grant focused on MDs or MD-PhDs who are continuing their training in translational laboratory-based research in brain diseases.

 

Dr. Dichter has won several prestigious awards including the Javits Award from the NINDS, a Fulbright Fellowship, the Solomon Berson Distinguished Alumnus Award from New York University, the Airing Lectureship at the University of Cincinatti, the American Society for Pharmacology and Experimental Therapeutics Award for Research in Antiepileptic Drugs and The William G. Lennox Award from the American Epilepsy Society and the President’s Award at Queens College.  Dr. Dichter is a past president of the American Epilepsy Society. 

Professor Patrick Couvreur

Patrick Couvreur is Full Professor of Pharmacy at the Paris-Sud University and holder of the chair of “Innovation Technologique” (2009-2010) at the prestigious « Collège de France ». He is appointed as a Senior Member of the “Institut Universitaire de France” since 2009. He is also the recipient of an “ERC Advanced Grant” (2010-2015) and of an “ERC Proof of Concept” (2015-2016). He has hold many important national and international academic positions as Director of the UMR CNRS 8612 (a CNRS associated departement gathering together more than 120 researchers in the drug delivery field), Director of the Doctoral School “Therapeutic Innovation” (over 300 PhD students at Paris-Sud University), founder member of the pole of competitivity MEDICEN, Extraordinary Professor at the University of Louvain (Belgium), member of the board of governors of many international scientific organizations (ie. The International Pharmaceutical Federation FIP, the Controlled Release Society CRS, the European Federation of Pharmaceutical Scientists, APGI etc.).

Prof Patrick Couvreur’s contributions in the field of drug delivery, nanomedicine and drug targeting are highly recognized around the world with more than 500 peer review research publications (Google Scholar H-index 118 and Thomson Reuters H-index 86), some of them in prestigious journals (Nature Nanotechnology, Nature Materials, Nature Communications, Proceedings of the National Academy of Sciences, Angewandte Chemie, Cancer Research, Journal of American Chemical Society etc.). His research is interdisciplinary, aiming at developping new nanomedicines for the treatment of severe diseases. This research is at the interface between Physico-Chemistry of Colloids, Polymer Chemistry, Material Science, Cellular and Molecular  Biology and Experimental Pharmacology.

Patrick Couvreur’s research has led to the funding of two start-up companies (Bioalliance and Medsqual). Bioalliance (now ONXEO) entered the stock market in 2005 and a nanomedicine invented in Couvreur’s lab is currently finishing phase III clinical trial for the treatment of the hepatocarcinoma.

The major scientific contribution of Patrick Couvreur to the Pharmaceutical Sciences is also recognized by numerous international (the “2004 Pharmaceutical Sciences World Congress Award”, the prestigious “Host Madsen Medal”, the “European Pharmaceutical Scientist Award” of the European Federation of Pharmaceutical Sciences, the European Inventor Award 2013 given by the European Patent Office and the Higuchi Award 2015, Japan) and national awards (the “Prix Galien 2009” and the “Médaille de l’Innovation 2012 of the CNRS). His appointment as a member of eight academies (Académie des Sciences, Académie des Technologies, Académie Nationale de Médecine and Académie Nationale de Pharmacie in France, as well as the Académie Royale de Médecine in Belgium, the Royal Academy of Pharmacy in Spain, the United States National Academy of Medicine and the United States National Academy of Engineering) is another recognition of major scientific and scholarly contributions of Patrick Couvreur.

Dr. Waseem Malick

Dr. Waseem Malick , Ph.D. is a retired pharmaceutical R&D executive with over 35 years of academic and industrial experience . He has had an extensive career in the industry previously serving as Vice President and Global Head of Pharmaceutical and Analytical R&D at Hoffmann-La Roche .

Prior to his 32 years service at Roche , he was Assistant Professor of Pharmaceutics at Wayne State University , Detroit .  His research interests include drug product development, formulation and drug delivery research. He has published 110 research papers, 169 abstracts and presented extensively in the area of drug delivery research. He was elected as fellow of the American Association of Pharmaceutical Scientists (AAPS) and has received several honors and awards. He has served on Board of Directors of non-profit organizations, Scientific Advisory Boards and has held adjunct appointments at universities. He received his Ph.D. in Pharmaceutics from the University of Michigan, Ann Arbor and M.S. from Columbia University, New York.

Dr. Donald Tomalia

Donald Tomalia is a world-renowned leader in molecular research and the creator of dendrimers. He is Director of the National Dendrimer & Nanotechnology Center and Distinguished Professor/Research Scientist in the Department of Chemistry - Central Michigan University and external faculty at the University of Wisconsin (Madison)- School of Pharmacy.

 

Donald A. Tomalia is the CEO/Founder of NanoSynthons LLC and National Dendrimer & Nanotechnology Center; Adjunct Professor (Department of Chemistry) University of Pennsylvania, PA and Affiliate Professor (Department of Physics) Virginia Commonwealth University, VA. 

 

Dr. Tomalia received his B.A. in Chemistry from the University of Michigan and Ph.D. in Physical-Organic Chemistry from Michigan State University while working at The Dow Chemical Company. He founded three dendrimer-based nanotechnology companies; namely: NanoSynthons LLC (2010), Dendritic Nanotechnologies Inc. (2001) (acquired by Starpharma, Melbourne, Australia) and Dendritech Inc. (1992) (acquired by the Dow Chemical Co., Midland, MI USA). Tomalia holds over 135 US patents and has over 265 peer reviewed publications largely focused on dendrimers and dendrimer-based nanomedicine. Recently, Dr. Tomalia was inducted as a AAAS Fellow (2016) for his pioneering contributions to nanotechnology and nanomedicine, particularly for the discovery of new macromolecular architectures including dendrimers, poly(oxazolines) and a new nanoperiodic concept for unifying nanoscience. Other positions currently held by Dr. Tomalia include: Scientific Advisory Board CLINAM, European Foundation for Clinical Nanomedicine; Sr. Scientific Advisor to the European Union CosmoPHOS Nano Project (2012-present). Dr. Tomalia also serves as Faculty Member, Faculty 1000 Biology; Associate Editor, Journal of Nanoparticle Research (Springer); Editorial Advisory Board, Nanomedicine (Elsevier) and Current Bionanotechnology.